



Seashore Organic Medicine

APPOINTMENT AND RESIGNATIONS OF DIRECTORS

November 4, 2015, Vancouver, B.C. – Seashore Organic Medicine Inc. (“SOM” or the “Company”) (CSE: SOM) is pleased to announce that Lui Franciosi has been appointed to Board of Directors effective November 4th, 2015 and will also assume position as interim Chief Financial Officer replacing Alexander Polevoy.

Mr. Franciosi possesses a range of skills related to the operation of small and mid-sized companies. He has overseen basic & clinical sciences of various drug development programmes, financial management, investor relations, & general office administration. Mr. Franciosi is the former Chief Operating Officer (COO) for Verona Pharma PLC, having overseen the business & clinical operations. He has over 17 years of experience providing independent clinical trials consultant services, supporting companies and universities in Canada, United Kingdom, the Netherlands, Italy, and Malaysia. In addition, he is currently the Executive Director of Royal City Manor., a Fraser Health-licensed long term care facility, wherein his responsibilities include managing approximately 220 unionized staff and caring for 165 complex care residents, and he is also an Adjunct Professor in the Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine with University of British Columbia.

Mr. Franciosi's education includes Research Fellow - King's College London (UK), Post-Doctoral Fellow - GlaxoSmithKline (UK) & Leiden University (NL), PhD, MSc and BSc in Pharmacology & Therapeutics – University of British Columbia (CA).

Concurrent with the appointment of Lui Franciosi, Mr. Alexander Polevoy and Vlad Voskoboinikov have stepped down from all positions held by them with the Company. The Company is grateful for all of their prior support and services. As the Company is indebted to Mr. Voskoboinikov and a numbered company controlled by Mr. Polevoy for an amount of approximately \$250,000 in relation to the Company's acquisition, through its subsidiary Sechelt Organic Marijuana Corp., of land in Sechelt, British Columbia, the Company has also caused a mortgage over such land to be granted to Mr. Voskoboinikov and the numbered company controlled by Mr. Polevoy as security over such land.

About Seashore Organic Medicine

Seashore Organic Medicine is a Canadian Securities Exchange (CSE) listed company based in Sechelt, British Columbia. Through its wholly owned subsidiary, Sechelt Organic Marijuana Corp., has applied to Health Canada for a medical marijuana production and distribution license under the Marijuana for Medical Purposes Regulations (the “MMPR”).

On behalf of the Board of Directors
SEASHORE ORGANIC MEDICINE INC.

"Leonard Werden"
Leonard Werden
President & CEO

Further information about the Company is available on our website at www.seashoremachine.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com.

Investor and Public Relations Contact



Seashore Organic Medicine

Seashore Organic Medicine Inc.
Leonard Werden
President & CEO
Telephone: +1.604.885.5500
Email: info@seashoremachine.com
Website: www.seashoremachine.com

The CSE has not reviewed, nor approved or disapproved the content of this press release.

Forward-Looking Information

This press release may include forward-looking information within the meaning of Canadian securities legislation concerning the business of the Company. Forward-looking information is based on certain key expectations and assumptions made by the management of the Company, including future plans for development of technologies by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. The Company disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.